Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives

Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a pr...

Descripción completa

Detalles Bibliográficos
Autor principal: Pasca, Samantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020573/
https://www.ncbi.nlm.nih.gov/pubmed/35465188
http://dx.doi.org/10.2147/JBM.S242219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020573/
https://www.ncbi.nlm.nih.gov/pubmed/35465188
http://dx.doi.org/10.2147/JBM.S242219

Ejemplares similares